Philip Morris Net Profit Margin 2010-2022 | PM
Current and historical net profit margin for Philip Morris (PM) from 2010 to 2022. Net profit margin can be defined as net Income as a portion of total sales revenue. Philip Morris net profit margin for the three months ending June 30, 2022 was .
| Philip Morris Net Profit Margin Historical Data |
| Date |
TTM Revenue |
TTM Net Income |
Net Margin |
| 2022-06-30 |
$31.80B |
$9.06B |
28.47% |
| 2022-03-31 |
$31.57B |
$9.00B |
28.50% |
| 2021-12-31 |
$31.41B |
$9.08B |
28.92% |
| 2021-09-30 |
$30.75B |
$8.97B |
29.19% |
| 2021-06-30 |
$30.07B |
$8.86B |
29.46% |
| 2021-03-31 |
$29.13B |
$8.63B |
29.64% |
| 2020-12-31 |
$28.69B |
$8.04B |
28.01% |
| 2020-09-30 |
$28.96B |
$7.67B |
26.49% |
| 2020-06-30 |
$29.16B |
$7.26B |
24.90% |
| 2020-03-31 |
$30.21B |
$7.64B |
25.29% |
| 2019-12-31 |
$29.81B |
$7.17B |
24.05% |
| 2019-09-30 |
$29.59B |
$7.47B |
25.23% |
| 2019-06-30 |
$29.45B |
$7.82B |
26.54% |
| 2019-03-31 |
$29.48B |
$7.69B |
26.09% |
| 2018-12-31 |
$29.63B |
$7.90B |
26.65% |
| 2018-09-30 |
$30.42B |
$6.68B |
21.96% |
| 2018-06-30 |
$30.39B |
$6.40B |
21.07% |
| 2018-03-31 |
$29.58B |
$5.99B |
20.24% |
| 2017-12-31 |
$28.75B |
$6.02B |
20.94% |
| 2017-09-30 |
$-8.63B |
$7.04B |
-81.58% |
| 2017-06-30 |
$3.84B |
$7.00B |
182.51% |
| 2017-03-31 |
$15.96B |
$7.01B |
43.92% |
| 2016-12-31 |
$26.69B |
$6.95B |
26.04% |
| 2016-09-30 |
$74.14B |
$6.49B |
8.75% |
| 2016-06-30 |
$73.62B |
$6.49B |
8.81% |
| 2016-03-31 |
$73.34B |
$6.59B |
8.98% |
| 2015-12-31 |
$73.91B |
$6.85B |
9.27% |
| 2015-09-30 |
$75.48B |
$7.20B |
9.54% |
| 2015-06-30 |
$77.39B |
$7.41B |
9.58% |
| 2015-03-31 |
$79.68B |
$7.37B |
9.25% |
| 2014-12-31 |
$80.11B |
$7.46B |
9.31% |
| 2014-09-30 |
$80.56B |
$7.84B |
9.73% |
| 2014-06-30 |
$79.85B |
$8.02B |
10.05% |
| 2014-03-31 |
$79.28B |
$8.29B |
10.46% |
| 2013-12-31 |
$80.03B |
$8.53B |
10.66% |
| 2013-09-30 |
$79.38B |
$8.64B |
10.88% |
| 2013-06-30 |
$78.34B |
$8.53B |
10.88% |
| 2013-03-31 |
$77.90B |
$8.72B |
11.19% |
| 2012-12-31 |
$77.39B |
$8.75B |
11.31% |
| 2012-09-30 |
$76.53B |
$8.54B |
11.16% |
| 2012-06-30 |
$77.64B |
$8.69B |
11.20% |
| 2012-03-31 |
$77.84B |
$8.78B |
11.28% |
| 2011-12-31 |
$76.35B |
$8.54B |
11.19% |
| 2011-09-30 |
$75.28B |
$8.39B |
11.14% |
| 2011-06-30 |
$71.51B |
$7.85B |
10.97% |
| 2011-03-31 |
$68.66B |
$7.43B |
10.82% |
| 2010-12-31 |
$67.71B |
$7.23B |
10.67% |
| 2010-09-30 |
$66.91B |
$7.03B |
10.50% |
| 2010-06-30 |
$66.55B |
$7.01B |
10.53% |
| 2010-03-31 |
$64.38B |
$6.57B |
10.20% |
| 2009-12-31 |
$62.08B |
$6.34B |
10.22% |
| Sector |
Industry |
Market Cap |
Revenue |
| Consumer Staples |
Tobacco Products |
$156.830B |
$82.223B |
|
Philip Morris International (PMI) is a leading international tobacco company working to deliver a smoke-free future and evolving its portfolio for the long term to include products outside of the tobacco and nicotine sector. The company's current product portfolio primarily consists of cigarettes and smoke-free products, including heat-not-burn, vapor and oral nicotine products, which are sold in markets outside the U.S. Since 2008, PMI has invested more than USD 9 billion to develop, scientifically substantiate and commercialize innovative smoke-free products for adults who would otherwise continue to smoke, with the goal of completely ending the sale of cigarettes. This includes the building of world-class scientific assessment capabilities, notably in the areas of pre-clinical systems toxicology, clinical and behavioral research, as well as post-market studies.
|
